A Phase 3 interventional study of Itraconazole and Vfend - voriconazole in Antifungal Prophylaxis of Invasive Fungal Infections, sponsored by Pfizer. Completed at 49 sites in 12 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2015-11-20.
Sponsored by Pfizer · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Invasive Fungal Infections with a site in United Kingdom — none open to participants now, none under way, none of them phase 3. Invasive Fungal Infections · United Kingdom.
Among the 10 studies in Invasive Fungal Infections with a site in United Kingdom, this one is the only one that started in 2006, is one of 5 in phase 3, and was the 2nd registered.
136 studies on the registry are indexed under Invasive Fungal Infections; 33 are open to participants now.
Browse Invasive Fungal Infections studies →None of the 10 studies in Invasive Fungal Infections with a site in United Kingdom is open now. The open studies under Invasive Fungal Infections, anywhere →
Of the 20 Invasive Fungal Infections studies recruiting now, 12 (60%) set no upper age limit and 5 (25%) stop at 75 or younger; 9 take children under 18; 2 take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 1 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 489 is above the median of 70 across 67 interventional studies indexed under Invasive Fungal Infections.
Median enrollment 252 across the 9 interventional studies, 20 across the 1 observational. Of the 9 that completed or were terminated, 4 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 10 have an industry lead sponsor. The 7 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Pfizer has 7 studies filed under Invasive Fungal Infections — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 10 studies in Invasive Fungal Infections with a site in United Kingdom, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Study is to compare antifungal prophylaxis of Voriconazole and Itraconazole in subjects who have had a Stem Cell Transplant. The success of the end point will be measured using evidence of Infection, drug compliance and survival.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Itraconazole
Drug: Vfend - voriconazole
Prophylaxis
Prophylaxis
Also known as: Vfend
Success at Day 180: Percent of Responders (Randomization Strata)
Percent of responders (by randomization strata) with success of antifungal prophylaxis at 180 days after allogeneic hematopoietic stem cell transplant (HSCT). Success: alive at Day 180 (Visit 9), had not developed a breakthrough proven or probable invasive fungal infection (IFI) by Visit 9, and received full course of study drug prophylaxis without interruption of greater than 14 days in total during the prophylaxis period; defined as failure if these criteria were not met. Additionally, if subject withdrew from study completely before Visit 9, imputed as failure at Visit 9 (programmatically).
Time frame: Day 180 (Visit 9)
Success at Day 100: Percent of Responders (Randomization Strata)
Percent of responders (by randomization strata) with success of antifungal prophylaxis at 100 days after allogeneic HSCT. Success defined as: alive at Day 100 (Visit 7), had not developed a breakthrough proven or probable IFI by Visit 7, and received full course of study drug prophylaxis without an interruption of \>14 days in total during the prophylaxis period; defined as failure if these criteria were not met. Additionally, if subject withdrew from study completely before Visit 7, imputed as failure at Visit 7 (programmatically).
Time frame: Day 100 (Visit 7)
Time to Breakthrough Invasive Fungal Infection (IFI)
Summary of time (in days) from start of prophylaxis to first recorded occurrence of breakthrough proven or probable IFI.
Time frame: Day 1 up to Day 180 (Visit 9)
Percent of Subjects With Occurrence of Breakthrough IFI
Percent of subjects with occurrence of breakthrough IFI (proven or probable). Included all subjects in the MITT population.
Time frame: Day 1 up to Day 100 (Visit 7) and Day 180 (Visit 9)
Survival: Percent of Subjects Who Died at or Before Day 180
Percent of subjects who died at or before Day 180, derived from the crude death rate. All subjects in the MITT population included in this proportion.
Time frame: Day 1 up to Day 180 (Visit 9)
Time to Discontinuation of Study Treatment
Time in days to discontinuation of study treatment defined as the number of days from first dose to last dose inclusive as recorded in the dosing log.
Time frame: Day 1 up to Day 180 (Visit 9)
Survival: Percent of Subjects Who Died Within 1 Year
Percent of subjects who died within 1 year after transplant, derived from the crude death rate. All subjects in the MITT population included in this proportion. Only deaths up until and including 365 days after first dose of study medication included in the analysis.
Time frame: Day 1 up to 1 year (Day 365)
Duration of Treatment
Median duration in days of treatment. Treatment is defined as the total number of days on which subjects took medication.
Time frame: Day 1 up to Day 180
Percent of Subjects With Use of Other Systemic Antifungal Agents as Empirical or Therapeutic Treatment
Percent of subjects who used other systemic antifungal agents as empirical or therapeutic treatment, defined as either empirical: subject took a systemic antifungal agent at any time after the day of first dose of medication and did not develop a breakthrough proven or probable IFI during the study or therapeutic: subject developed a breakthrough proven or probable IFI.
Time frame: Day 1 up to Day 180
| Milestone | Voriconazole | Itraconazole |
|---|---|---|
| Started | 234 | 255 |
| Completed | 176 | 175 |
| Not completed | 58 | 80 |
| Withdrew: Death | 35 | 38 |
| Withdrew: Adverse event | 15 | 13 |
| Withdrew: Failure of prophylaxis | 1 | 1 |
| Withdrew: Fungal breakthrough infection | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: Withdrawal by subject | 2 | 12 |
| Withdrew: Other | 5 | 14 |
Percent of responders (by randomization strata) with success of antifungal prophylaxis at 180 days after allogeneic hematopoietic stem cell transplant (HSCT). Success: alive at Day 180 (Visit 9), had not developed a breakthrough proven or probable invasive fungal infection (IFI) by Visit 9, and received full course of study drug prophylaxis without interruption of greater than 14 days in total during the prophylaxis period; defined as failure if these criteria were not met. Additionally, if subject withdrew from study completely before Visit 9, imputed as failure at Visit 9 (programmatically).
| percent of participants | Voriconazole | Itraconazole |
|---|---|---|
| Myeloablative/matched related (n=66, 85) | 59.1 | 44.7 |
| Myeloablative/mismatched unrelated (n=59, 58) | 52.5 | 25.9 |
| Non-myeloablative/matched related (n=58, 57) | 34.5 | 28.1 |
| Non-myeloablative/mismatched unrelated (n=41, 41) | 46.3 | 26.8 |
Percent of responders (by randomization strata) with success of antifungal prophylaxis at 100 days after allogeneic HSCT. Success defined as: alive at Day 100 (Visit 7), had not developed a breakthrough proven or probable IFI by Visit 7, and received full course of study drug prophylaxis without an interruption of \>14 days in total during the prophylaxis period; defined as failure if these criteria were not met. Additionally, if subject withdrew from study completely before Visit 7, imputed as failure at Visit 7 (programmatically).
| percent of participants | Voriconazole | Itraconazole |
|---|---|---|
| Myeloablative/matched related (n=66, 85) | 65.2 | 50.6 |
| Myeloablative/mismatched unrelated (n=59, 58) | 55.9 | 27.6 |
| Non-myeloablative/matched related (n=58, 57) | 43.1 | 38.6 |
| Non-myeloablative/mismatched unrelated (n=41, 41) | 48.8 | 36.6 |
Summary of time (in days) from start of prophylaxis to first recorded occurrence of breakthrough proven or probable IFI.
| days | Voriconazole | Itraconazole |
|---|---|---|
| Time to Breakthrough Invasive Fungal Infection (IFI) | 119.0 ± 28.58 | 77.0 ± 77.08 |
Percent of subjects with occurrence of breakthrough IFI (proven or probable). Included all subjects in the MITT population.
| percent of participants | Voriconazole | Itraconazole |
|---|---|---|
| Day 100 | 0.9 | 1.2 |
| Day 180 | 1.3 | 1.7 |
Percent of subjects who died at or before Day 180, derived from the crude death rate. All subjects in the MITT population included in this proportion.
| percent of participants | Voriconazole | Itraconazole |
|---|---|---|
| Survival: Percent of Subjects Who Died at or Before Day 180 | 15.6 | 15.4 |
Time in days to discontinuation of study treatment defined as the number of days from first dose to last dose inclusive as recorded in the dosing log.
| days | Voriconazole | Itraconazole |
|---|---|---|
| Time to Discontinuation of Study Treatment | 88.7 ± 61.41 | 71.5 ± 52.21 |
Percent of subjects who died within 1 year after transplant, derived from the crude death rate. All subjects in the MITT population included in this proportion. Only deaths up until and including 365 days after first dose of study medication included in the analysis.
| percent of participants | Voriconazole | Itraconazole |
|---|---|---|
| Survival: Percent of Subjects Who Died Within 1 Year | 25.9 | 30.7 |
Median duration in days of treatment. Treatment is defined as the total number of days on which subjects took medication.
| days | Voriconazole | Itraconazole |
|---|---|---|
| Duration of Treatment | 96.0 (1 to 258) | 68.0 (3 to 223) |
Percent of subjects who used other systemic antifungal agents as empirical or therapeutic treatment, defined as either empirical: subject took a systemic antifungal agent at any time after the day of first dose of medication and did not develop a breakthrough proven or probable IFI during the study or therapeutic: subject developed a breakthrough proven or probable IFI.
| percent of participants | Voriconazole | Itraconazole |
|---|---|---|
| Percent of Subjects With Use of Other Systemic Antifungal Agents as Empirical or Therapeutic Treatment | 40.6 | 49.4 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Voriconazole | — | 111/234 (47.4%) | 228/234 (97.4%) |
| Itraconazole | — | 95/255 (37.3%) | 252/255 (98.8%) |
| Event | Voriconazole | Itraconazole |
|---|---|---|
| PyrexiaGeneral disorders | 19/234 | 11/255 |
| Cytomegalovirus infectionInfections and infestations | 9/234 | 11/255 |
| Graft versus host diseaseImmune system disorders | 9/234 | 8/255 |
| DiarrhoeaGastrointestinal disorders | 8/234 | 9/255 |
| VomitingGastrointestinal disorders | 1/234 | 7/255 |
| Acute graft versus host diseaseImmune system disorders | 2/234 | 7/255 |
| NauseaGastrointestinal disorders | 2/234 | 6/255 |
| Acute graft versus host disease in intestineImmune system disorders | 5/234 | 6/255 |
| Cystitis haemorrhagicRenal and urinary disorders | 3/234 | 6/255 |
| Acute graft versus host disease in liverImmune system disorders | 5/234 | 1/255 |
| Event | Voriconazole | Itraconazole |
|---|---|---|
| Mucosal inflammationGeneral disorders | 115/234 | 142/255 |
| DiarrhoeaGastrointestinal disorders | 100/234 | 132/255 |
| PyrexiaGeneral disorders | 105/234 | 101/255 |
| VomitingGastrointestinal disorders | 78/234 | 103/255 |
| NauseaGastrointestinal disorders | 86/234 | 91/255 |
| HeadacheNervous system disorders | 63/234 | 69/255 |
| Febrile neutropeniaBlood and lymphatic system disorders | 51/234 | 68/255 |
| RashSkin and subcutaneous tissue disorders | 48/234 | 45/255 |
| Abdominal painGastrointestinal disorders | 45/234 | 50/255 |
| CoughRespiratory, thoracic and mediastinal disorders | 45/234 | 42/255 |
| Age, Customized(participants) | Voriconazole | Itraconazole | Total |
|---|---|---|---|
| <18 years | 9 | 11 | 20 |
| Between 18 and 44 years | 106 | 119 | 225 |
| Between 45 and 64 years | 104 | 115 | 219 |
| >=65 years | 15 | 10 | 25 |
| Age, Continuous(years) | Voriconazole | Itraconazole | Total |
|---|---|---|---|
| Mean | 43.3 ± 14.4 | 42.7 ± 14.6 | 43.0 ± 14.5 |
| Sex: Female, Male(Participants) | Voriconazole | Itraconazole | Total |
|---|---|---|---|
| Female | 96 | 100 | 196 |
| Male | 138 | 155 | 293 |
The record gives a start of Mar 2006, a primary completion of Feb 2009 and a completion of Feb 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2010, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Voriconazole